23:17:27 EDT Tue 23 Apr 2024
Enter Symbol
or Name

Login ID:

Aeterna Zentaris shareholders approve AGM resolutions

2023-06-14 16:39 ET - News Release

Mr. Peter Edwards reports


All items of business were approved at Aeterna Zentaris Inc.'s virtual annual general and special meeting of shareholders (AGM) held today.

Results of the AGM

At the AGM, all items of business were approved. The individuals noted in the attached table were elected as directors of the company.

At the AGM, Deloitte LLP was appointed as the company's auditor.

The company is an eligible interlisted issuer as such term is defined in the Toronto Stock Exchange company manual. As an eligible interlisted issuer, the company has relied on an exemption pursuant to Section 602.1 of the TSX company manual from Section 613 of the TSX company manual, the effect of which is that, subject to the satisfaction of certain conditions prescribed by the TSX, the company will not have to comply with certain Canadian requirements in connection with the company's long-term incentive plan. As a result, shareholders were not asked to approve the unallocated entitlements under the company's long-term incentive plan at the AGM.

For full voting details, please see the report of voting results filed on SEDAR and EDGAR.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The company's lead product, macimorelin (Macrilen; Ghryvelin), is the first and only United States Food and Drug Administration- (FDA) and European Commission-approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The company is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need.

Aeterna Zentaris is dedicated to the development of its therapeutic asset and has established a preclinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease).

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.